BIO Bio-Rad Laboratories Inc

  1. Stocks
  2. Healthcare
  3. NYSE: BIO

Price (delayed)

$282.12

Market cap

$7.55B

P/E Ratio

48.39

Dividend/share

N/A

EPS

$5.83

Enterprise value

$8.42B

?
Relative Growth: Rel. Growth: 26
Relative Strength: Rel. Strength: 45
Relative Valuation: Rel. Valuation: 51
Relative Profitability: Rel. Profitability: 54

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The EPS has soared by 108% YoY but it has plunged by 79% from the previous quarter
The net income has soared by 108% YoY but it has shrunk by 78% QoQ
The company's quick ratio fell by 47% YoY and by 44% QoQ
The company's gross margin fell by 3% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bio-rad.com/
Peers: TMO BDX HBIO A

Key stats

What are the main financial stats of BIO

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
0.36%
1 week
-2.7%
1 month
-1.95%
1 year
19.78%
YTD
-6.89%
QTD
1.21%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.59B
Gross profit
$1.34B
Operating income
$57.6M
Net income
$168.8M
Gross margin
51.9%
Net margin
6.5%
The net margin has surged by 108% year-on-year but it has dropped by 78% since the previous quarter
The net income has soared by 108% YoY but it has shrunk by 78% QoQ
BIO's operating margin has dropped by 78% year-on-year but it is up by 22% since the previous quarter
BIO's operating income has dropped by 77% year-on-year but it is up by 22% since the previous quarter

Price vs fundamentals

How does BIO's price correlate with its fundamentals

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
BIO P/E details
P/E
48.39
P/B
1.11
P/S
2.94
EV/EBIT
31.01
EV/EBITDA
31.01
EV/Sales
3.25
The EPS has soared by 108% YoY but it has plunged by 79% from the previous quarter
BIO's P/B is 15% below its 5-year quarterly average of 1.3
The equity has contracted by 8% from the previous quarter but it has grown by 2.6% YoY
The stock's price to sales (P/S) is 32% less than its 5-year quarterly average of 4.3

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 110% YoY but it has plunged by 74% from the previous quarter
The company's return on invested capital has surged by 110% YoY but it has shrunk by 73% QoQ
The ROE has soared by 108% year-on-year but it has dropped by 78% since the previous quarter
Bio-Rad Laboratories's ROA has soared by 108% YoY but it has plunged by 78% from the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's quick ratio fell by 47% YoY and by 44% QoQ
The company's current ratio fell by 46% YoY and by 43% QoQ
The debt is 80% smaller than the equity
The equity has contracted by 8% from the previous quarter but it has grown by 2.6% YoY
Bio-Rad Laboratories's debt to equity has increased by 5% from the previous quarter but it has decreased by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.